Beyond Data Transparency: Innovation Across the Drug Development Lifecycle
Once a drug company has clinical trial transparency (CTT) capabilities in place, new opportunities to drive value further along the drug development life cycle also emerge.
In this presentation, General Manager Sarah Lyons discusses how risk-based, statistical anonymization protects patient privacy while enabling insight-rich data, helping you:
- Achieve trial transparency
- Meet regulatory deadlines
- Drive drug differentiation
- Accelerate data science
If you’re looking to comply with drug authorization regulations, share insight-rich data with health researchers, or scale anonymization for internal data strategies and drug development, this presentation is for you.